Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1-Reference-Cited by-同舟云学术

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1

Published:2016-10-06 Issue:14 Volume:128 Page:1834-1844
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gong Jia-Nan¹²^ORCID,Khong Tiffany³,Segal David¹²^ORCID,Yao Yuan¹²⁴,Riffkin Chris D.¹,Garnier Jean-Marc¹²,Khaw Seong Lin¹²⁵,Lessene Guillaume¹²⁶^ORCID,Spencer Andrew³,Herold Marco J.¹²^ORCID,Roberts Andrew W.¹²⁷⁸^ORCID,Huang David C. S.¹²^ORCID

Affiliation:

1. The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia;

2. Department of Medical Biology, University of Melbourne, Melbourne, Australia;

3. Myeloma Research Group, Australian Centre for Blood Diseases, Monash University and the Alfred Hospital, Melbourne, Australia;

4. School of Medicine, Tsinghua University, Beijing, China;

5. Royal Children’s Hospital, Melbourne, Australia;

6. Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Australia;

7. Department of Clinical Haematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Melbourne, Australia; and

8. Victorian Comprehensive Cancer Centre, Parkville, Australia

Abstract

Key Points Only a minority of myeloma cell lines are killed when the prosurvival BCL2 or BCLXL are selectively inhibited with BH3 mimetic compounds. In contrast, targeting MCL1 readily killed ∼70% of the myeloma cell lines tested, including both low-passage and well-established ones.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/14/1834/1396529/1834.pdf

Reference51 articles.

1. Multiple myeloma.;Röllig;Lancet,2015

2. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.;Vincent Rajkumar;Am J Hematol,2014

3. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).;Ocio;Leukemia,2014

4. p53 haploinsufficiency and functional abnormalities in multiple myeloma.;Teoh;Leukemia,2014

5. Clinical significance of TP53 mutation in myeloma.;Chng;Leukemia,2007

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies;Blood Advances;2024-07-29

2. Improved drug target deconvolution with PISA‐DIA using an extended, overlapping temperature gradient;PROTEOMICS;2024-05-20

3. Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy;Blood;2024-05-02

4. Development of recombinant protein-based nanoparticle systems for inducing tumor cell apoptosis: In vitro evaluation of their cytotoxic and apoptotic effects on cancer cells;Journal of Drug Delivery Science and Technology;2024-05

5. Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity;Frontiers in Oncology;2024-04-08